CN201337642Y - Novel immune isolation unit - Google Patents
Novel immune isolation unit Download PDFInfo
- Publication number
- CN201337642Y CN201337642Y CNU2008201242629U CN200820124262U CN201337642Y CN 201337642 Y CN201337642 Y CN 201337642Y CN U2008201242629 U CNU2008201242629 U CN U2008201242629U CN 200820124262 U CN200820124262 U CN 200820124262U CN 201337642 Y CN201337642 Y CN 201337642Y
- Authority
- CN
- China
- Prior art keywords
- isolation unit
- immune isolation
- outer package
- immune
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Prostheses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The utility model discloses an immune isolation unit, comprising a round-cornered pocket-like external package and an interface through which cells can be perfused, wherein a gel layer is coated on the outer surface of the pocket-like external package, and through holes with apertures with consistent size are uniformly distributed on the pocket-like external package; the pocket-like external package of the immune isolation unit is made of PTFE membrance, and the gel layer is coated with Agarose-bFGF hydrogel. The surface coating of the immune isolation unit can promote blood vessels to be generated on the surface of the immune isolation unit, and increase the biocompatibility of the immune isolation unit and the body; the corner of the outer surface of the immune isolation unit is in a round shape, so that the surrounding tissues can not be injured during transplantation; the immune isolation unit is provided with an infusion connector which is easy to inject and extract the cells; and the immune isolation unit can be used as an artificial alternative unit for cell transplantation.
Description
Technical field
This utility model relates to biomedical sector, is specifically related to be used for the structure of the immune spacer assembly of cellular transplantation therapy.
Background technology
Proposition and constantly development along with bioartificial liver's notion nineties in 20th century, external biological type artificial liver is that a new way has been opened up in the treatment of liver failure, research focus mainly concentrates on and utilizes hepatocyte to substitute liver function, but immunologic rejection is the bottleneck of its development.The microcapsule technology that grew up in recent years has effective immune isolation barrier, along with the development of this technology, has enlarged for the hepatocyte source, has solved donor and has lacked this difficult problem.The research that microencapsulated hepatocyte is implanted in the various hepatopathys of treatment is just receiving increasing concern, and its clinical effectiveness also is worth expectation more.
Microcapsule (Microcapsules) technology is a kind of technology of utilizing natural or synthetic macromolecule filming material (capsule material) embedding of liquid or solid medicine (capsule core material) bag to be formed diameter 1-5000 μ m (being generally 5-250 μ m) tiny capsules.Cyst membrane has permeable membrane or semipermeable membrane character, but methods such as capsule core material mat pressure, pH value, temperature or extraction are disengaged.According to the different in kind of encapsulation techniques and capsule core material, capsule material, the capsule grain of microcapsule can be the putamina type of the outer encapsulation material of capsule core material or the mosaic that capsule core material is embedded in the capsule material.The capsule grain can be sphere, grape cluster shape, surface smoothing or different shape such as folding and irregular.But the microcapsule constituent ratio of preparation is more single at present, and cyst membrane is generally only made lapping and used, and does not have other function, and is poor with biocompatible, and after in transplanting enters body, controllability is extremely low, for clinical practice brings great risk.
Therefore, on the basis of microcapsule,, be the developing direction of novel immune spacer assembly by in conjunction with having good permeability and having the new membrane material in certain homogeneous aperture.
Summary of the invention
The purpose of this utility model provides a kind of and the good novel immune isolated location that is used for cellular transplantation therapy of biocompatible.
A kind of immune isolated location of this utility model comprises the pocket sample outer package of a fillet and is installed in wherein the capsule heart, is characterized in that the outer surface of pocket sample outer package also is coated with a gel layer.
Described immune isolated location wherein is evenly distributed with the through hole of pore size unanimity in the outer package of pocket sample.The outer package of pocket sample is provided with the interface of a perfusion capsule heart.
Described immune isolated location, the outer package of pocket sample is made by poly tetrafluoroethylene.Gel layer is applied by low gel point agarose-basic fibroblast growth factor hydrogel and forms.
Adopt above technical scheme, this utility model immunity isolated location surface scribbles agarose-basic fibroblast growth factor (Agarose-bFGF) hydrogel layer, it can impel blood vessel to generate on immune isolated location surface, increases the biocompatibility of immune isolated location and body; Immunity isolated location outer surface corner is rounded, can not injure surrounding tissue in the migration process; Have transfusion connector, be easy to inject and extract cell.
Description of drawings
Fig. 1 is this utility model immunity isolated location structural representation; A partly is an overall structure, and B partly is the structural representation of B unit section shown in the A.
The specific embodiment
This utility model is a kind of novel immune isolated location, can be used for as the artificial substituting unit in the cell transplantation.
Referring to shown in Figure 1, shown the basic structure of immune isolated location.This unit comprises the pocket sample outer package 1 of a fillet, wherein is evenly distributed with the through hole 11 of pore size unanimity in the pocket sample outer package 1, and is provided with an interface 12 that can pour into the capsule heart; The construction features that this utility model is the most outstanding is the outside of pocket sample outer package 1, also is coated with a gel layer 4 (referring to B part among Fig. 1).This utility model is that the edge of two-layer housing material 1a and 1b is formed inner cell apothecas 3 with binding agent 2 bonding backs, gel rubber material is coated in housing material 1a and 1b outer surface again and forms gel layer 4.
Concrete, the material that can be used for this utility model making has:
Can be used as the making material of pocket sample outer package 1: poly tetrafluoroethylene (PTFE, OmniporeMembrane Filter, JVWP09025; Millipore) through-hole aperture 0.1 μ m, film radius 90mm, wherein through-hole aperture size uniformity.
Can be used as the making material of gel layer 4: low gel point agarose (Low Gelling TemperatureAgarose, sigma company), heparin sodium (Heparin, sigma,～170 USP units/mg), and basic fibroblast growth factor (bFGF, sigma); This utility model uses gel coat to generate on immune isolated location surface to impel blood vessel.The Agarose-bFGF hydrogel is aseptic nontoxic, and is harmless.Agarose (Agarose) must have the characteristic of low gel point.
Interface 12: transfusion device coupling part; For cell injects and takes out needed passage.
The capsule heart: can be cell, for example adipose-derived mescenchymal stem cell, the mescenchymal stem cell of derived from bone marrow, amniotic fluid stem cell etc.
Binding agent: adhesive of medical, medical silica-gel (DOW
SILICONE MEDICALADHESIVE SILICONE TYPE-A), aseptic nontoxic, human body is had no adverse effects.
Can adopt following method to make this utility model:
1. be 90mm with radius, the aperture is the poly tetrafluoroethylene (Omnipore of 0.1 μ m; Millipore), bonding with silica gel, make length and width and be 3.5 * 1.8 centimetres pocket sample outer package;
2. the transfusion device coupling part is cut about 3.3 centimetres, on one side and along inserting in the outer package of above-mentioned pocket sample, outside the part of connection syringe is exposed to, the pocket sampling device is sealed fully with silica gel;
3. 5% LGTAgarose is put into the pressure cooker inner high voltage, it is dissolved fully; Water-bath is transferred to 37-39 ℃ in advance, the Agarose that takes out is put into water-bath rapidly; With Heparin (100U/mL ,～170USP units/mg, 250mg) and bFGF (50ng-100ng) and the rapid mixing of not solidified Agarose;
4. above-mentioned not solidified mixture is spread upon the pocket surface of having made equably, and put into 4 ℃ of refrigerators, treat to take out behind the gel formation;
With the 1ml injection will be to be transplanted cell slowly inject in the bag by the connector in the outer package of pocket sample, with shears connector is cut rapidly after finishing, and with silica gel rapidly with fracture sealing, put 4 ℃ of refrigerators and wait to transplant.
Claims (5)
1, a kind of immune isolated location comprises the pocket sample outer package of a fillet and is installed in wherein the capsule heart, it is characterized in that the outer surface of pocket sample outer package also is coated with a gel layer.
2, according to the described immune isolated location of claim 1, it is characterized in that, wherein be evenly distributed with the through hole of pore size unanimity in the outer package of pocket sample.
According to claim 1 or 2 described immune isolated locations, it is characterized in that 3, wherein the outer package of pocket sample is provided with the interface of a perfusion capsule heart.
According to the described immune isolated location of claim 3, it is characterized in that 4, wherein the outer package of pocket sample is made by poly tetrafluoroethylene.
According to the described immune isolated location of claim 3, it is characterized in that 5, wherein gel layer is applied by low gel point agarose-basic fibroblast growth factor hydrogel and forms.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2008201242629U CN201337642Y (en) | 2008-12-05 | 2008-12-05 | Novel immune isolation unit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNU2008201242629U CN201337642Y (en) | 2008-12-05 | 2008-12-05 | Novel immune isolation unit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN201337642Y true CN201337642Y (en) | 2009-11-04 |
Family
ID=41233177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNU2008201242629U Expired - Fee Related CN201337642Y (en) | 2008-12-05 | 2008-12-05 | Novel immune isolation unit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN201337642Y (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111050815A (en) * | 2017-08-30 | 2020-04-21 | 富士胶片株式会社 | Angiogenesis agent and method for producing same |
| US11439960B2 (en) | 2017-08-30 | 2022-09-13 | Fujifilm Corporation | Cell transplant device and method of manufacturing the same |
| US12029636B2 (en) | 2016-11-03 | 2024-07-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Stacked tissue encapsulation device systems with or without oxygen delivery |
| US12115332B2 (en) | 2020-10-30 | 2024-10-15 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and systems for encapsulation devices for housing cells and agents |
-
2008
- 2008-12-05 CN CNU2008201242629U patent/CN201337642Y/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12029636B2 (en) | 2016-11-03 | 2024-07-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Stacked tissue encapsulation device systems with or without oxygen delivery |
| CN111050815A (en) * | 2017-08-30 | 2020-04-21 | 富士胶片株式会社 | Angiogenesis agent and method for producing same |
| US11439960B2 (en) | 2017-08-30 | 2022-09-13 | Fujifilm Corporation | Cell transplant device and method of manufacturing the same |
| US11471564B2 (en) | 2017-08-30 | 2022-10-18 | Fujifilm Corporation | Angiogenic agent and method of manufacturing the same |
| US12115332B2 (en) | 2020-10-30 | 2024-10-15 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and systems for encapsulation devices for housing cells and agents |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Colton | Implantable biohybrid artificial organs | |
| EP0862391B1 (en) | Retrievable bioartificial implants | |
| Iacovacci et al. | The bioartificial pancreas (BAP): Biological, chemical and engineering challenges | |
| CA1319794C (en) | Intravascular artificial organ | |
| CA2103705C (en) | Spinal fluid driven artificial organ | |
| JP5524824B2 (en) | Improved bioreactor surface | |
| Song et al. | An intravascular bioartificial pancreas device (iBAP) with silicon nanopore membranes (SNM) for islet encapsulation under convective mass transport | |
| Storrs et al. | Preclinical development of the Islet Sheet | |
| JP2019005626A5 (en) | ||
| US6023009A (en) | Artificial pancreas | |
| JP3291297B2 (en) | Bioartificial endocrine device | |
| WO1991000119A1 (en) | Implantable device | |
| WO1996030492A1 (en) | Filter device | |
| JPH08504615A (en) | Implantable and refillable biohybrid artificial pancreas and refilling method thereof | |
| CN201337642Y (en) | Novel immune isolation unit | |
| KR20120128630A (en) | Perfusion culture method and perfusion culture device for organ or tissue | |
| JP2009533340A (en) | Multi-membrane immunoisolation system for cell grafts | |
| Dowling et al. | Artificial liver support in acute liver failure | |
| CN112587730A (en) | Composite cell scaffold and preparation method thereof | |
| US20050209556A1 (en) | Implantable intravascular delivery device | |
| CN202490188U (en) | Micro-capsule implant | |
| CN113271892A (en) | Implant and use thereof | |
| CN110709137A (en) | Macroencapsulated therapeutic cells and methods of use thereof | |
| US20020151055A1 (en) | Novel artificial pancreas | |
| CN214388359U (en) | Composite cell scaffold |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: SOUTH CHINA CENTER FOR STEM CELL BIOLOGY AND REGENERATIVE MEDICINE OF ACADEMY OF MILITARY MEDICAL SCIENCES Assignor: Inst. of Field Blood Transfusion, Academy of Military Medical Sciences, PLA Contract record no.: 2014990000847 Denomination of utility model: Novel immune isolation unit Granted publication date: 20091104 License type: Exclusive License Record date: 20141104 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091104 Termination date: 20151205 |
|
| EXPY | Termination of patent right or utility model |